Search
AN2898
go.drugbank.com/drugs/DB16039InvestigationalAN2898 is under investigation in clinical trial NCT01301508 (Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-moderate Atopic Dermatitis).
Apitegromab
go.drugbank.com/drugs/DB16096InvestigationalApitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Somatorelin
go.drugbank.com/drugs/DB12656InvestigationalSomatorelin has been used in trials studying the treatment of Aging, Elderly, Sleep Disorders, Hormone Deficiency, and Mild Cognitive Impairment.
Categories: Tests for Pituitary FunctionSobuzoxane
go.drugbank.com/drugs/DB21119ExperimentalSobuzoxane is a small molecule drug. The usage of the INN stem '-oxan(e)' in the name indicates that Sobuzoxane is a benzodioxane derivative.
Categories: Topoisomerase II Inhibitors(R)-acetoin
go.drugbank.com/drugs/DB04364ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Synonyms: (R)-2-acetoin, (R)-acetoin(S)-acetoin
go.drugbank.com/drugs/DB02788ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
Ibopamine
go.drugbank.com/drugs/DB13316ExperimentalCategories: Compounds used in a research, industrial, or household settingPF-04620110
go.drugbank.com/drugs/DB14887InvestigationalPF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
Categories: Diacylglycerol O-AcyltransferaseSpartalizumab
go.drugbank.com/drugs/DB14892InvestigationalSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).